Reaktion #1122395

ord-08c413e7d8314a8885ba343f781bb900

Reaktionsgleichung

CN1CCN(Cc2ccc(OC3CNC3)cc2Cl)CC1
49A
CN1CCN(Cc2ccc(OC3CNC3)cc2Cl)CC1
1-(4-(Azetidin-3-yloxy)-2-chlorobenzyl)-4-methylpiperazine
CCOC(=O)c1nnc(-c2ccc(OC)cc2)o1
ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate
COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCN(C)CC5)c(Cl)c4)C3)o2)cc1
49
Ausbeute 64.0%
COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCN(C)CC5)c(Cl)c4)C3)o2)cc1
(3-(3-chloro-4-((4-methylpiperazin-1-yl)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone
Ausbeute 64.0%

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Vorschrift

Using a similar protocol as described in Example 16 employing 49A (2.7 g, 9.1 mmol) and ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate (2.5 g, 10.0 mmol) as starting materials afforded 2.9 g (64%) of 49 as a solid. 1H NMR (500 MHz, CDCl3): δ 2.28 (s, 3H), 2.3-2.7 (m, 8H), 3.56 (s, 2H), 3.88 (s, 3H), 4.32 (dd, 1H), 4.63 (dd, 1H), 4.74 (dd, 1H), 5.05 (m, 1H), 5.11 (m, 1H), 6.67 (dd, 1H), 6.78 (d, 1H), 7.02 (d, 2H), 7.39 (d, 1H), 8.09 (d, 2H), MS (APCI+) m/z 498 [M+H]+, LC purity: 95%.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08546375B2uspto-grants-2013_10